Provention Bio is a biopharmaceutical company. Co.'s pipeline of product candidates in development includes: PRV-031, an anti-CD3 monoclonal antibody (mAb) for the delay or prevention of clinical Type 1 Diabetes (T1D); PRV-101, a Coxsackie Virus B (CVB) vaccine to prevent acute CVB infections and to prevent the CVB-triggered autoimmune damage to pancreatic beta cells that may progress to T1D and damage to intestinal cells that may lead to celiac disease; PRV-3279, a bispecific scaffold molecule targeting the B-cell surface proteins for the treatment of systemic lupus erythematosus; and PRV-015, an anti-interleukin 15 mAb for the treatment of gluten-free diet non-responsive celiac disease. The PRVB stock yearly return is shown above.
The yearly return on the PRVB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PRVB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|